IL17A and psoriasis vulgaris: Ixekizumab is a humanized IgG4 IL-17A monoclonal antibody, and secukinumab is a fully human IgG1 IL-17A monoclonal antibody, both highly effective in treating patients with moderate-to-severe plaque psoriasis in three phases of clinical trials [26].